# Osiris Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/osiris-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Columbia, US
- Website: www.osiris.com
- Total disclosed funding: $10M
- Latest round: Series E (Oct 16, 1996)
- Investors on record: 1

## About

Osiris Therapeutics, Inc. focuses on regenerative medicine solutions, including innovative therapies aimed at treating a variety of diseases and conditions through advanced cellular technology.Osiris Therapeutics, Inc. is a biotechnology company specializing in regenerative medicine. Founded in 1992 in Columbia, Maryland, US, it has completed 12 deals, with its most recent deal occurring on August 7, 2006. The company underwent a pivotal acquisition by Smith & Nephew plc in March 2019 for approximately USD 660 mn. The co-founders include Kevin Kimberlin and Royce Liao, while Alexander Sutter currently serves as CEO.Osiris.com specializes in domain monetization and sales through its platform, Bodis.com. The core offering revolves around facilitating the sale or lease of domain names, providing owners with an efficient avenue to monetize their digital assets. This service is particularly beneficial for investors, startups, and established companies seeking to acquire premium domain names that enhance their online presence and branding. The primary end-use case addresses the demand for high-value domain names, enabling businesses to establish credibility and improve visibility in the digital landscape. The platform primarily serves clients in North America, Europe, and Asia, catering to a diverse clientele that includes small businesses, entrepreneurs, and large corporations focused on enhancing their digital strategies.In 2018, Osiris Therapeutics, Inc. generated revenue of USD 142.82 mn, with an EBITDA of USD 10.73 mn. The revenue model is built around domain sales and leasing agreements, primarily through the Bodis platform, facilitating transactions between domain owners and potential buyers or lessees.Following its recent acquisition, Osiris Therapeutics, Inc. is expected to leverage Smith & Nephew’s extensive global network to enhance its product offerings and expand into new markets. The funding from the acquisition will likely be allocated toward the development of innovative regenerative medicine products and facilitating entry into emerging markets identified in Asia and Europe by 2023. This strategy aims to position Osiris Therapeutics favorably in the evolving biotechnology landscape.

## Funding rounds

- Series E, Oct 16, 1996, $10M — New Venturetec

## Investors

- New Venturetec (https://capitalatlas.ai/funds/new-venturetec) — Series E